220 related articles for article (PubMed ID: 2154328)
1. Purine metabolism of human glioblastoma in vivo.
Pillwein K; Chiba P; Knoflach A; Czermak B; Schuchter K; Gersdorf E; Ausserer B; Murr C; Goebl R; Stockhammer G
Cancer Res; 1990 Mar; 50(5):1576-9. PubMed ID: 2154328
[TBL] [Abstract][Full Text] [Related]
2. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
[TBL] [Abstract][Full Text] [Related]
3. Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues.
Natsumeda Y; Prajda N; Donohue JP; Glover JL; Weber G
Cancer Res; 1984 Jun; 44(6):2475-9. PubMed ID: 6327016
[TBL] [Abstract][Full Text] [Related]
4. Purine metabolism in myeloid precursor cells during maturation. Studies with the HL-60 cell line.
Lucas DL; Webster HK; Wright DG
J Clin Invest; 1983 Dec; 72(6):1889-900. PubMed ID: 6139386
[TBL] [Abstract][Full Text] [Related]
5. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
Jayaram HN; Zhen W; Gharehbaghi K
Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
[TBL] [Abstract][Full Text] [Related]
6. Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells.
Natsumeda Y; Ikegami T; Olah E; Weber G
Cancer Res; 1989 Jan; 49(1):88-92. PubMed ID: 2461800
[TBL] [Abstract][Full Text] [Related]
7. Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.
Pillwein K; Jayaram HN; Weber G
Blut; 1988 Aug; 57(2):97-100. PubMed ID: 3165681
[TBL] [Abstract][Full Text] [Related]
8. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
[TBL] [Abstract][Full Text] [Related]
9. De novo synthesis of purine nucleotides in human peripheral blood leukocytes. Excessive activity of the pathway in hypoxanthine-guanine phosphoribosyltransferase deficiency.
Brosh S; Boer P; Kupfer B; de Vries A; Sperling O
J Clin Invest; 1976 Aug; 58(2):289-97. PubMed ID: 956368
[TBL] [Abstract][Full Text] [Related]
10. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
11. Targets and markers of selective action of tiazofurin.
Weber G; Natsumeda Y; Pillwein K
Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
[TBL] [Abstract][Full Text] [Related]
12. Involvement of guanine nucleotides in superoxide release by fluoride-treated neutrophils. Implications for a role of a guanine nucleotide regulatory protein.
English D; Rizzo MT; Tricot G; Hoffman R
J Immunol; 1989 Sep; 143(5):1685-91. PubMed ID: 2547872
[TBL] [Abstract][Full Text] [Related]
13. Adenine metabolism of Ehrlich mouse ascites cells in proliferating and resting phase of tumor growth.
Grune T; Siems W; Uhlig R; Jakstadt M
Biochem Int; 1992 Feb; 26(2):199-209. PubMed ID: 1558533
[TBL] [Abstract][Full Text] [Related]
14. A comparison of purine metabolism and nucleotide pools in normal and hypoxanthine-guanine phosphoribosyltransferase-deficient neuroblastoma cells.
Snyder FF; Cruikshank MK; Seegmiller JE
Biochim Biophys Acta; 1978 Nov; 543(4):556-69. PubMed ID: 718989
[TBL] [Abstract][Full Text] [Related]
15. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
Lee HJ; Pawlak K; Nguyen BT; Robins RK; Sadée W
Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
[TBL] [Abstract][Full Text] [Related]
16. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
[TBL] [Abstract][Full Text] [Related]
17. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
18. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
[TBL] [Abstract][Full Text] [Related]
19. Regulation of purine and pyrimidine metabolism by insulin and by resistance to tiazofurin.
Weber G; Lui MS; Jayaram HN; Pillwein K; Natsumeda Y; Faderan MA; Reardon MA
Adv Enzyme Regul; 1985; 23():81-99. PubMed ID: 3907307
[TBL] [Abstract][Full Text] [Related]
20. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
